Neurocrine Biosciences IncNeurocrine Biosciences Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Alternative companies in the rating peer group for Neurocrine Biosciences Inc are displayed. This report of Neurocrine Biosciences Inc incorporates data from across the web and also from available disclosures by Neurocrine Biosciences Inc. Scroll down to the bottom of the page for potential risks for Neurocrine Biosciences Inc based on sector, geography and size.

Neurocrine Biosciences Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.6; made up of an environmental score of 4.6, social score of 6.0 and governance score of 8.0.

SDG Transparency Score for Neurocrine Biosciences Inc 
Low
0 - 3

6.6

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Neurocrine Biosciences Inc 
4.6

Environmental

6.0

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
446STADA Arzneimittel AG
6.7
High
446Valeo Pharma Inc
6.7
High
483Neurocrine Biosciences Inc
6.6
High
483Bal Pharma Ltd
6.6
High
483Adicet Bio Inc
6.6
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Neurocrine Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc offer flexible work?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose water use targets?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Neurocrine Biosciences Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Neurocrine Biosciences Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Neurocrine Biosciences Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose its waste policy?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose energy use targets?

LockedSign up for free to unlock

Does Neurocrine Biosciences Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Neurocrine Biosciences Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Neurocrine Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Sorry!

Failed to process!